Expression Analysis of miR-29b in Malignant and Benign Breast Tumors: A Promising Prognostic Biomarker for Invasive Ductal Carcinoma With a Possible Histotype-Related Expression Status

Papachristopoulou, Georgia; Papadopoulos, Emmanuel I.; Nonni, Afrodite; Rassidakis, George Z.; Scorilas, Andreas

doi:10.1016/j.clbc.2017.11.007

Cited by 12 publications

(15 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, overexpression for ≥ 3 d results in aneuploidy in human BCa cells 223 .miR-29a-3p−0.97stimulates migration and invasion; Repressed by MYC, YYI, NFκB, CEBPA and stimulated by p53 224 .OncomiR and tumor suppressormiR-29b-3p−0.71Low expression in breast tumors correlates with reduced OS and DFS 225 . Lower expression in invasive ductal adenocarcinoma versu s lobular carcinomas and elevated in ER+ versus ER- breast tumors 58 .. Expression increased by GATA2 which suppresses MMP9, ANGPTL4, VEGF , and LOX promoting differentiation, blocking EMT to suppress metastasis 226 .…”

Section: Resultsmentioning

confidence: 99%

“…Both miR-29a and miR-29b are considered tumor suppressors in breast cancer and their repression results in in cancer stem cell expansion in vitro 57 . Progestins repress miR-29a and miR-29b in ER+/PR+ breast cancer cells 58 and “PR action in breast cancer: stimulation of metastasis” was identified in MetaCore analysis. Patients with ductal carcinoma and elevated miR-29b levels had a significantly longer disease-free survival (DFS) and lower risk to relapse 58 .…”

Section: Resultsmentioning

confidence: 99%

“…Progestins repress miR-29a and miR-29b in ER+/PR+ breast cancer cells 58 and “PR action in breast cancer: stimulation of metastasis” was identified in MetaCore analysis. Patients with ductal carcinoma and elevated miR-29b levels had a significantly longer disease-free survival (DFS) and lower risk to relapse 58 . miR-29b-3p was downregulated in exosomes of patients with breast cancer recurrence, suggesting a role for miR-29b-3p in inhibition of breast cancer progression and recurrence 59 .…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

HNRNPA2/B1 is upregulated in endocrine-resistant LCC9 breast cancer cells and alters the miRNA transcriptome when overexpressed in MCF-7 cells

Klinge

Piell

Tooley

et al. 2019

Sci Rep

View full text Add to dashboard Cite

MicroRNAs are dysregulated in breast cancer. Heterogeneous Nuclear Ribonucleoprotein A2/B1 (HNRNPA2/B1) is a reader of the N(6)-methyladenosine (m6A) mark in primary-miRNAs (pri-miRNAs) and promotes DROSHA processing to precursor-miRNAs (pre-miRNAs). We examined the expression of writers, readers, and erasers of m6A and report that HNRNPA2/B1 expression is higher in tamoxifen-resistant LCC9 breast cancer cells as compared to parental, tamoxifen-sensitive MCF-7 cells. To examine how increased expression of HNRNPA2/B1 affects miRNA expression, HNRNPA2/B1 was transiently overexpressed (~5.4-fold) in MCF-7 cells for whole genome miRNA profiling (miRNA-seq). 148 and 88 miRNAs were up- and down-regulated, respectively, 48 h after transfection and 177 and 172 up- and down-regulated, respectively, 72 h after transfection. MetaCore Enrichment analysis identified progesterone receptor action and transforming growth factor β (TGFβ) signaling via miRNA in breast cancer as pathways downstream of the upregulated miRNAs and TGFβ signaling via SMADs and Notch signaling as pathways of the downregulated miRNAs. GO biological processes for mRNA targets of HNRNPA2/B1-regulated miRNAs included response to estradiol and cell-substrate adhesion. qPCR confirmed HNRNPA2B1 downregulation of miR-29a-3p, miR-29b-3p, and miR-222 and upregulation of miR-1266-5p, miR-1268a, miR-671-3p. Transient overexpression of HNRNPA2/B1 reduced MCF-7 sensitivity to 4-hydroxytamoxifen and fulvestrant, suggesting a role for HNRNPA2/B1 in endocrine-resistance.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

HNRNPA2/B1 is upregulated in endocrine-resistant LCC9 breast cancer cells and alters the miRNA transcriptome when overexpressed in MCF-7 cells

Klinge

Piell

Tooley

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…miRNAs have gained increasing relevance because of their functions in the growth of cancer cells such as hyperplasia and migration [8]. In recent years, several studies including the research of Papachristopoulou et al [13] and Guo et al [14] illuminated the potential relationship between miRNA and breast tumors, while their researches only clarify the role of one particular miRNA in breast neoplasms. For other correlative studies, they paid more attention on the relationship between clinicopathological characteristics and miRNAs [15,16].…”

Section: Discussionmentioning

confidence: 99%

Breast Invasive Ductal Carcinoma Diagnosis with A Three-Mirna Panel in Serum

Chen

Wang

et al. 2021

Biomark. Med.

View full text Add to dashboard Cite

Aim: Breast cancer, especially invasive ductal carcinoma (IDC), is the cause of a great clinical burden. miRNA could be considered as a noninvasive biomarkers for IDC diagnosis. Materials & methods: Two hundred and sixty participants (135 IDC patients and 125 healthy controls) were enrolled in a three-cohort study. The expression of 28 miRNAs in serum were detected with quantitative reverse transcription-PCR. Bioinformatic analysis was used for predicting the target genes of three selected miRNAs. Results: The expression level of seven miRNAs (miR-9-5p, miR-34b-3p, miR-1-3p, miR-146a-5p, miR-20a-5p, miR-34a-5p, miR-125b-5p) was discrepant at the validation cohort. Through statistical test, a three-miRNA panel (miR-9-5p, miR-34b-3p, miR-146a-5p) was significant for IDC diagnosis (AUC = 0.880, sensitivity = 86.25%, specificity = 81.25%). Conclusion: The three-miRNA panel in serum could be used as a noninvasive biomarker in the diagnosis of IDC.

show abstract

“…Accumulating evidence has demonstrated that the expression level of miR-29b is lower in variety of malignancies and cancer cell lines than that in normal tissues or cell lines 21 . miR-29b expression has been correlated with clinicopathological characteristics in patients with colorectal cancer 30 - 32 , breast cancer 33 , and osteosarcoma 34 patients, suggesting its potential to serve as a biomarker for diagnosis and prognosis of cancer. miR-29b has been documented to negatively affect tumorigenesis and cancer progression by regulating cell proliferation, survival, and metastasis 28 , Whilst overexpression of miR-29b can also inhibit tumorigenesis 35 and angiogenesis 36 - 38 .…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-29b-3p enhances radiosensitivity through modulating WISP1-mediated mitochondrial apoptosis in prostate cancer cells

Mao¹,

Tang²,

Tang³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Radiotherapy is frequently applied for clinically localized prostate cancer while its efficacy could be significantly hindered by radioresistance. MicroRNAs (miRNAs) are important regulators in mediating cellular responses to ionizing radiation (IR), and strongly associate with radiosensitivity in many cancers. In this study, enhancement of radiosensitivity by miR-29b-3p was demonstrated in prostate cancer cell line LNCaP in vitro. Results showed that miR-29b-3p expression was significantly upregulated in response to IR from both X-rays and carbon ion irradiations. Knockdown of miR-29b-3p resulted in radioresistance while overexpression of miR-29b-3p led to increased radiosensitivity (showing reduced cell viability, suppressed cell proliferation and decreased colony formation). In addition, miR-29b-3p was found to directly target Wnt1-inducible-signaling protein 1 (WISP1). Inhibition of WISP1 facilitated the mitochondrial apoptosis pathway through suppressing Bcl-XL expression while activating caspase-3 and poly (ADP-ribose) polymerase (PARP). The results indicated that miR-29b-3p was a radiosensitizing miRNAs and could enhance radiosensitivity of LNCaP cells by targeting WISP1. These findings suggested a novel treatment to overcome radioresistance in prostate cancer patients, especially those with higher levels of the WISP1 expression.

show abstract

Expression Analysis of miR-29b in Malignant and Benign Breast Tumors: A Promising Prognostic Biomarker for Invasive Ductal Carcinoma With a Possible Histotype-Related Expression Status

Cited by 12 publications

References 28 publications

HNRNPA2/B1 is upregulated in endocrine-resistant LCC9 breast cancer cells and alters the miRNA transcriptome when overexpressed in MCF-7 cells

HNRNPA2/B1 is upregulated in endocrine-resistant LCC9 breast cancer cells and alters the miRNA transcriptome when overexpressed in MCF-7 cells

Breast Invasive Ductal Carcinoma Diagnosis with A Three-Mirna Panel in Serum

MicroRNA-29b-3p enhances radiosensitivity through modulating WISP1-mediated mitochondrial apoptosis in prostate cancer cells

Contact Info

Product

Resources

About